News

AB Science Advances Cancer Treatment with AB8939 and Venetoclax

AB Science Advances Cancer Treatment with AB8939 and Venetoclax

AB Science's Promising Developments in Leukemia Treatment

AB Science SA (Euronext - FR0010557264 - AB) is making significant strides in oncology, particularly in the treatment of acute myeloid leukemia (AML). The company has shared its initial Phase 1 trial results confirming the combination of AB8939 with venetoclax, a regimen that shows considerable potential for patients facing treatment challenges.

Impressive Phase 1 Trial Results

The recent presentation from AB Science highlights the remarkable efficacy of the AB8939 and venetoclax combination. These results are particularly noteworthy as they were achieved in a difficult subset of patients: those in their third or fourth line of treatment, some of whom had previously shown resistance to venetoclax when combined with other therapies.

Key Highlights from the Presentation

Initial findings indicate that:

  • The combination treatment has a disease control rate of 100%, showcasing the effectiveness in all patients treated.
  • Both therapies together yield a partial response rate of 100%, with one patient reaching complete remission.
  • This favorable outcome came after just one treatment cycle that lasted 14 days.

Physicians involved in the trials, like Dr. Nicholas J. Short from the MD Anderson Cancer Center, point to the encouraging data, suggesting significant activity of AB8939 alone and in conjunction with venetoclax in high-risk AML subtypes.

Addressing the Need in Acute Myeloid Leukemia

AML presents a continual challenge in the medical field. Despite the available drugs, about 70% of patients will experience relapse. The condition remains the most lethal form of leukemia, making the need for effective treatment solutions urgent. AB Science’s AB8939 offers a dual action against the disease, targeting both leukemia cells and cancer stem cells, which are often responsible for relapses.

Understanding the Mechanism of AB8939

AB8939’s mechanism focuses on two key areas:

  • It disrupts microtubule dynamics, preventing the proliferation of leukemia cells.
  • It also specifically targets leukemia stem cells, inhibiting ALDH, which solidifies its role in reducing relapse rates.

Non-Clinical Data and Future Implications

According to the latest non-clinical data, AB8939 demonstrates significant activity against leukemia cell lines showing resistance to standard treatments like Ara-C. The data also suggest positive outcomes in vivo when used in combination with venetoclax, enhancing overall survival rates.

Next Steps for AB Science

The company’s strategy moving forward includes concluding the Phase 1 study and initiating an expansion study targeting approximately 15 AML patients. This will further validate the combination's efficacy and could pave the way for broader clinical applications.

AB Science is exploring three potential registrational studies in conjunction with regulatory agencies, focusing on applying this combination as an initial or subsequent line of treatment for patients with adverse genetic conditions.

Market Potential and Conclusion

The addressable market for treatments in relapsed or refractory AML is substantial, estimated at over EUR 2 billion annually. With their innovative approaches, AB Science is poised to provide more effective solutions for these patients.

AB8939 Positioning in Oncology

AB Science also discusses the intellectual property surrounding AB8939, ensuring its innovations and treatments remain protected well into the next decade. As research and clinical trials continue to unfold, the anticipation builds around the future of AB Science in revolutionizing AML treatment.

Frequently Asked Questions

What is AB8939?

AB8939 is an investigational medication being developed by AB Science to treat acute myeloid leukemia, focusing on disruptive mechanisms against leukemia cells and cancer stem cells.

What results were found in the Phase 1 trial?

The Phase 1 trial showed a disease control rate of 100% and a complete remission in one patient after just one treatment cycle, demonstrating strong efficacy.

How does AB8939 work?

AB8939 works by disrupting microtubule dynamics, preventing leukemia cell proliferation and specifically targeting leukemia stem cells.

What is the next phase for AB Science?

AB Science plans to finish Phase 1 trials and launch expansion studies involving AML patients to further establish the efficacy of the AB8939 and venetoclax combination.

What is the market potential for this treatment?

The potential market for treatment of relapsed or refractory AML is estimated to exceed EUR 2 billion, emphasizing the significant need for effective therapies in this area.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Mars Sets $2 Billion Debt Tender With Kellanova Notes

Updated Category News Views 108

A two-billion-dollar vacuum cleaner just switched on inside Mars’s debt stack, and the timing is anything but casual. On November 20, Mars fixed the pricing for cash tender offers spanning selected Mars and Kellanova senior notes, with holders facing a 5:00 p.m. New York deadline that same day. This is the kind of filing that looks like bond-market plumbing until you...

Continue Reading
U.S. Employers Signal a Deeper Multilingual Skills Gap

Updated Category News Views 101

A language gap rarely makes the loudest noise in an earnings call, yet it can quietly wreck a sales effort, a hiring plan, or a customer relationship. ACTFL's updated 2026 employer study puts some hard edges around that problem: U.S. businesses say multilingual capability is not a nice cultural accessory. It is increasingly part of operating the business. Demand Has Moved...

Continue Reading
AlphaPoint's Approval Device Targets AI Attack Risk

Updated Category News Views 45

A Separate Screen May Be Worth More Than Another Patch AlphaPoint is taking a fairly old security instinct and aiming it at a very current headache: if the laptop is lying to the employee, do not let the laptop have the final say. Its newly introduced Approval Device is dedicated hardware with its own display, built to let authorized staff inspect and approve sensitive...

Continue Reading
D-Wave Investors Face December 15 Lead Plaintiff Clock

Updated Category News Views 103

Quantum dreams met a very earthly spreadsheet problem at D-Wave this summer. The proposed securities class action against D-Wave Quantum Inc. puts a hard date on the issue for investors who bought shares between February 26 and August 25, 2026: December 15, 2026 is the deadline to seek lead-plaintiff status. That does not mean every holder needs to march into court. It...

Continue Reading
Water Damage Coverage Has More Traps Than Homeowners Think

Updated Category News Views 29

A wet basement does not care one bit whether the water arrived dramatically or dripped in for months. That ugly distinction, though, can decide whether a homeowner has an insurance claim or a repair bill that lands with a thud. Kathy Thurmond-Edwards, an insurance expert in Memphis, Tennessee, lays out the dividing lines plainly: sudden pipe failures may be treated very...

Continue Reading
Birkenstock’s Athens Stores Put Brand Control to Work

Updated Category News Views 76

A 62-square-meter shop on Ermou Street can say plenty about a brand’s ambitions. Birkenstock is opening its first two Greek stores in Athens, moving beyond its existing wholesale and retail-partner presence with locations it can shape from the floorboards up. The first site at Ermou 18 is stated to have opened on November 12, 2026; the announcement itself is dated...

Continue Reading
Trump's Reagan Forum Speech Puts Defense in Focus Again

Updated Category News Views 118

A December podium in Simi Valley has suddenly become a market-relevant appointment. The Ronald Reagan Presidential Foundation and Institute says President Donald J. Trump will deliver the keynote at the 2026 Reagan National Defense Forum on Friday, December 4, at 3:00 p.m. Pacific time, or 6:00 p.m. Eastern. That is the whole hard fact pattern so far. No agenda, no...

Continue Reading
PCS Rental Prep Is About Control Before Distance Hits

Updated Category News Views 99

A vacant house can turn into a long-distance headache with startling speed. For military homeowners preparing for a PCS move, the useful point in Rhonda Leahy's guidance is not glamorous: settle the boring operational stuff before the moving boxes, travel orders, and new-duty-station chaos swallow the calendar. Renting out a former home is not merely collecting enough...

Continue Reading
TCL CSOT's Oxide Leap Gives LCD a Sharper Fight Ahead

Updated Category News Views 73

Fifty-one point six is the number that makes this announcement worth chewing on. TCL CSOT says it has moved ultrahigh-mobility oxide technology into mass production on an 8.6-generation line, clearing the 50 cm² V?¹ s?¹ threshold that has largely belonged to lab-talk and presentation slides. For display people, that is not decorative science. It could change the old...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 62

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading

Top 5 Most Recently Viewed Articles

Redsun Properties Faces $350 Million Bond Payment Crisis Ahead

Updated Category News Views 189

Redsun Properties Announces Inability to Pay Bond Chinese property developer Redsun Properties has communicated its inability to meet a $350 million bond payment, which is due shortly. This situation has raised considerable concern within the financial markets as it highlights the ongoing issues facing property developers in China. Details of the Bond Issue This bond,...

Continue Reading
Etruscus Resources Unveils Promising Findings at Zappa Target

Updated Category News Views 135

Etruscus Resources Makes Progress at Key Exploration Sites Etruscus Resources Corp. is thrilled to report on the encouraging findings from its exploration program at the Rock & Roll Property. This property is situated in the Golden Triangle region, known for its wealth of mineral resources. The exploration program, which included comprehensive rock sampling and geological...

Continue Reading
MetLife's Strategic Focus: Navigating Q3 2024 Earnings

Updated Category News Views 1091

MetLife Announces Q3 2024 Results and New Frontier Strategy In the third quarter of 2024, MetLife, Inc. (MET) reported adjusted earnings of $1.4 billion, translating to $1.93 per share. This reflects a decline from previous year figures, yet a 12% year-to-date increase in adjusted earnings per share (EPS) excluding notable items. The insurance powerhouse has seen positive...

Continue Reading
VEON Invests in Ukraine: Commitment to Digital Growth

Updated Category News Views 125

VEON's Commitment to Investing in Ukraine VEON Ltd. (NASDAQ: VEON), a leading global digital operator, has recently made significant news with its promise to enhance Ukraine’s telecommunications infrastructure. In collaboration with its fully-owned subsidiary, Kyivstar, VEON participated in the 2024 Yalta European Strategy (YES) Annual Meeting. At this event, the focus...

Continue Reading
Expanding Diabetes Care: From Monitoring to Change

Updated Category News Views 44

Breaking Ground at the AGP & DTx Summit Diabetes management ain't what it used to be, and the 4th AGP & DTx Summit in Shenzhen gave us an eyeful of change. Under the banner "Beyond Glucose," experts from all corners came together to talk shop about Continuous Glucose Monitoring (CGM) and how it might shake up diabetes care. CGM: More Than a Gadget See, CGM's not just a...

Continue Reading